Latest Period
Q1 2026
Security Snapshot
AMPHASTAR PHARMACEUTICALS IN - NOTE 2.000% 3/1 Institutional Ownership
CUSIP: 03209RAB9
13F Institutional Holders and Ownership History from Q3 2024 to Q2 2026
Institutions Reporting
36
Principal
$339,660,006
Price (% of par)
90.38%
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Debt / NOTE 2.000% 3/1
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F principal
- $339,660,006
- Total 13F market value
- $307,277,914
- Principal change
- +$2,299,000
- Market value change
- +$1,346,424
- Number of holders
- 36
- SEC-reported market price (% of par)
- 90.81%
Latest holder snapshot
3 signals
Issuer context
Names, identifiers, and filing context for this profile.
1 identity field
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- 03209RAB9 - AMPHASTAR PHARMACEUTICALS IN - NOTE 2.000% 3/1 is tracked under CUSIP 03209RAB9.
- 36 institutions reported positions in Q1 2026.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 36 to 11 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $307,277,914 to $108,408,506.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 36 institutions filings for Q1 2026.
Security key
03209RAB9
Latest holder period
Q1 2026
13F holders
36
13D/G owners
0
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03209RAB9:
As of 31 Mar 2026, 36 institutional investors reported holding $339,660,006 in principal (par value) of AMPHASTAR PHARMACEUTICALS IN - NOTE 2.000% 3/1.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q1 2026
Rows shown
1-8 of 8
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | $113,669,440 | $108,408,506 | +$23,610,892 | 90.81% | 11 |
| 2026 Q1 | $339,660,006 | $307,277,914 | +$1,346,424 | 90.38% | 36 |
| 2025 Q4 | $337,372,006 | $312,204,241 | +$35,882,119 | 92.48% | 42 |
| 2025 Q3 | $298,658,206 | $271,682,316 | +$15,400,429 | 90.9% | 44 |
| 2025 Q2 | $287,504,200 | $250,404,674 | -$1,633,019 | 86.66% | 42 |
| 2025 Q1 | $289,012,700 | $257,820,283 | -$20,287,313 | 88.89% | 39 |
| 2024 Q4 | $310,090,000 | $290,929,251 | -$11,267,553 | 93.11% | 36 |
| 2024 Q3 | $320,190,500 | $339,259,650 | +$336,118,248 | 105.6% | 35 |